Overview
The IM8 Revolution
Chapter
5
of
8
Building the Next Hims & Hers
The IM8 story begins with an introduction that changed everything. My good friend Michel Lamuniere, owner of Tatler Asia, introduced me to David Beckham. But this wasn't another celebrity endorsement pitch—this was about building something unprecedented together.
Our mission was simple yet ambitious: create the world's best supplement, one that would be uncompromisingly backed by science and deliver an exceptional taste experience. What made this extraordinary was that David agreed to become a co-founder—marking the first time in his illustrious career he had taken an ownership stake in the health supplements industry. Despite countless approaches from major corporations and ambitious entrepreneurs over the years, he had consistently said no. Until now.
"When someone of David Beckham's caliber puts his name and reputation behind a venture as a co-founder—after decades of turning down similar opportunities—you realize you're not just building a product, you're building a legacy."
This partnership transcended traditional celebrity endorsements. David wasn't lending his name; he was betting his reputation on our shared vision to revolutionize the supplement industry through uncompromising quality, rigorous science, and exceptional user experience. Together, we were determined to set a new standard that the entire industry would have to follow.
What happened next exceeded even our most optimistic projections. IM8 achieved something unprecedented in the supplement industry: we built the first supplement brand ever to reach $100 million in annual recurring revenue (ARR) within 11 months of launch.
The Growth Trajectory:
This represents the fastest growth to $100 million ARR in supplement industry history. For context, it took Hims & Hers, one of the most successful direct-to-consumer healthcare companies, significantly longer to achieve similar milestones. It even outpaces AI companies in terms of growth.
The partnership with Aryna Sabalenka, the World #1 tennis player, exemplifies how authentic products create organic relationships rather than manufactured endorsements. This wasn't a marketing strategy—it was a discovery story that began with her performance coach, Jason Stacy.
In January 2025, Jason first learned about IM8 and began researching the product. What caught his attention wasn't flashy marketing, but the substance: IM8 was NSF Certified for Sport, meaning it had been rigorously tested for over 280 banned substances—a critical requirement for elite athletes. After trying the product himself and experiencing great results, Jason suggested Aryna give it a try.
Within a few weeks, Aryna noticed a significant difference in her energy levels, recovery time, and cognitive function. But being the elite athlete she is, she didn't rush to judgment. For three months, she continued taking IM8, monitoring its effects on her training and performance. By the end of that period, it was clear to her: this was the real deal.
In April 2025, her team reached out to me with a simple message: "Aryna has been loving the product and can we partner together?" My response was immediate: "Of course!"
"When the world's #1 tennis player discovers your product organically, tests it for months, and then asks to partner with you—that's not marketing, that's validation."
What makes this partnership extraordinary is its authenticity. Aryna didn't just become an ambassador—she became a shareholder, investing her own money in the company. But the story doesn't end there. Her entire ecosystem—coaches, agents, and even family members—are now all on IM8. When a product is genuinely transformative, it spreads organically through the people who matter most.
Our scientific advisory board brings together 11 leading experts from academia, medicine, and space science. This group is absolutely amazing and I’m in constant whatsapp with so many of them on a daily basis!
What excites David and me most isn't just the financial metrics—it's the thousands of customer reviews telling us how great they feel after taking IM8 and how it has changed their lives. We receive testimonials about increased energy, improved recovery, enhanced mental clarity, and overall wellness improvements that go far beyond what typical supplements can deliver.
Given IM8's incredible success and trajectory toward becoming one of the fastest-growing supplement brands in history, the most common question I get is: "Why not just focus on IM8? Why complicate things by adding a Bitcoin treasury strategy?"
This is the fundamental question that drives our dual-engine approach, and the answer reveals why this strategy is not a complication but a strategic imperative.
The same pattern recognition that identified Honey's potential before it became obvious, that saw Alan's healthcare transformation opportunity before it was validated by a $4.5 billion valuation, now reveals why the intersection of healthcare growth and Bitcoin treasury management creates unprecedented value creation opportunities.
IM8's explosive growth creates substantial cash flows that need to be deployed strategically. Traditional cash management approaches—parking money in low-yield instruments that depreciate in real terms—represent a massive opportunity cost when you have the operational capabilities to pursue superior alternatives.
Our healthcare engine provides the operational stability and cash flow generation that enables sophisticated Bitcoin treasury management. Our Bitcoin treasury provides the financial appreciation that can accelerate healthcare expansion and create additional strategic flexibility.
This isn't about diversification for its own sake—it's about creating sustainable competitive advantages that single-engine companies cannot match. While competitors focus on single markets or single strategies, we're building a platform that creates value across multiple transformative trends simultaneously.
For the first time, Prenetics is providing full-year guidance for IM8's 2026 performance:
2026 Revenue Guidance: $160 million - $200 million
Market Expansion: North America, Europe, and key Asian markets
The phenomenal growth of IM8 is driving Prenetics toward becoming a billion-dollar company. This isn't just about building a successful supplement brand—it's about proving that the right combination of scientific rigor, authentic partnerships, and exceptional execution can create outcomes that seemed impossible to previous generations.
"IM8 isn't just growing fast—it's redefining what's possible in the supplement industry while providing the operational foundation for our dual-engine strategy."
The IM8 revolution demonstrates that when you combine uncompromising quality, authentic partnerships, scientific credibility, and exceptional execution, you can achieve growth rates that transform entire industries while building sustainable competitive advantages.
